Skip to main content


  • Research article
  • Open Access
  • Open Peer Review

Identification of young adults at risk of an accelerated loss of kidney function in an area affected by Mesoamerican nephropathy

Contributed equally
BMC Nephrology201920:21

  • Received: 2 July 2018
  • Accepted: 20 December 2018
  • Published:
Open Peer Review reports



After two-years of follow-up of 263 apparently healthy 18- to 30-year-old men in communities affected by Mesoamerican nephropathy (MeN), we identified three distinct case groups: a subgroup with (i) established renal dysfunction (case-group 1); individuals with (ii) a rapid decline in kidney function (case-group 2); and individuals with (iii) stable kidney function (non-cases). This paper investigates whether local tests are potentially useful for the timely identification of these case groups.


Creatinine levels were measured in local laboratories every six months for two years. Aliquots were sent to a centralized laboratory for measurements of cystatin C and creatinine levels. We investigated agreement between the locally and centrally measured creatinine-based Chronic Kidney disease Epidemiology Collaboration (CKD-EPI) equation for estimating the Glomerular Filtration Rate (eGFR). A logistic regression analysis was used to assess predictive factors for case groups 1 and 2 compared to non-cases. Predictive variables were locally measured eGFR, and urinary neutrophil gelatinase-associated lipocalin (uNGAL) levels. The discrimination performance of the model was assessed using the area under the receiver operating characteristic curve (AUC).


Considerable variation in local eGFR measurements was observed. The prediction model for case-group 1 included baseline kidney function and with or without uNGAL (AUC = 0.98, 95% confidence interval (CI), 0.91–1.00). The prediction model for case-group 2 also required eGFRScr at six and twelve months after baseline, with or without uNGAL levels (AUC = 0.88; 95% CI 0.80–0.99).


Established renal dysfunction was detected at a single time point using local measurements and uNGAL. For the detection of a rapid decline in kidney function over time, at least 2 more measurements at six and twelve months are needed.


  • Mesoamerican nephropathy
  • Chronic kidney disease of unknown aetiology
  • Prediction
  • Kidney function status
  • Serum creatinine
  • uNGAL
  • ROC
  • Nicaragua


Mesoamerican nephropathy (MeN) is a major public health and economic problem affecting rural and agricultural communities in Mesoamerica. Over the last decade, MeN, also known as chronic kidney disease of unknown aetiology (CKDu), has caused the deaths of thousands of vulnerable young male agricultural workers, particularly sugarcane workers and other workers (agricultural and non-agricultural) who work in extremely hot conditions along the Pacific coast of Mesoamerica [15]. MeN has devastating consequences for patients, family members, communities and the country, with patients who are diagnosed with the disease progressing to end stage renal disease as young and middle-aged adults. Renal replacement therapy options are expensive and limited in Mesoamerica, resulting in the high mortality of patients with MeN [6, 7].

MeN disease has some unique characteristics, including the absence of traditional risk factors (hypertension and diabetes) [1, 8, 9]. A recent systematic review identified that the male gender, living in lowlands, a family history of CKD and a high water-intake are associated with CKDu [10]. Some studies have reported elevated urinary neutrophil gelatinase-associated lipocalin (uNGAL) and N-acetyl-β-D-glucosaminidase (NAG) levels in sugarcane workers [11, 12]. Therefore, one current hypothesis is that MeN is caused by repetitive acute kidney injury due to multiple risk factors, such as working conditions and heat [1, 8].

We have recently conducted a community-based cohort study in the affected region. We used established biomarkers of kidney function (serum cystatin C (Scys) and serum creatinine (Scr) levels) that were measured in stored samples from baseline and 6-month follow-up visits in a central laboratory at the end of the study (five measures in total) to determine the decline in kidney function after 2 years of follow-up. [13, 14] Although we attempted to recruit people without established kidney disease at baseline, 25 people (10.5% of the cohort) who were apparently healthy but in fact had established kidney dysfunction at baseline were included. An additional sub-group of males (10.5% of the total cohort) exhibited an extremely rapid decline in kidney function of 18.2 mL/min/1.73 m2/year from normal levels [14]. The observed dramatic loss of renal function among a sizeable sub-group of an apparently healthy young population is a concern.

The local industries in Nicaragua have established baseline screening programmes for kidney dysfunction using a single local creatinine test [15]. Despite the use of this local screening programme, a sub-group of people with established kidney disease was recruited in our study; therefore, a question arises of whether other information is needed in addition to a single serum creatinine measurement to detect MeN. In addition, the identification of the subgroup that will experience a rapid decline in kidney function will be beneficial to provide advice (e.g., avoidance of known nephrotoxins, such as non-steroidal anti-inflammatory drugs) and potentially to implement interventions (e.g., improve work conditions, clean water etc., if these interventions are proven to be effective) to prevent or delay future kidney function loss. Serial measurements of serum creatinine levels over more than 2 years are not the usual practice in Nicaragua. Therefore, the purpose of this analysis is to determine if repeated local creatinine tests combined with urinary measurements of uNGAL levels can identify the subgroup of individuals at risk of a future rapid decline in kidney function.


Study population

These analyses are based on our existing community-based follow-up study of a decline in kidney function among affected communities in Nicaragua. The rationale and study design have been published elsewhere [13]. Briefly, we recruited 350 apparently healthy young adults aged 18–30 years without a known diagnosis of CKDu and traditional risk factors, and followed them for two years. All eligible healthy males and a sample of females from 9 communities in northwest Nicaragua were enrolled in our study. Biological samples, anthropometric measurements and questionnaire data were collected at baseline and then at six-month intervals. The outcome was the kidney function status, and we classified the participants into three categories: (i) established renal dysfunction; (ii) a rapid decline in kidney function; and (iii) stable kidney function [14].

Clinical measurements

Gold standard

All samples were analysed in a single batch to reduce time-dependent measurement errors in the assays after two years of follow-up. At the end of the follow-up period, stored (− 80 °C) serum aliquots from all study visits were transferred to the Clinical Trial Service Unit at Oxford University. Scr levels were quantified using a Beckman AU680 Chemistry Analyser (Jaffe compensated method) and calibrated against the IDMS-traceable creatinine standard. Scys levels were measured using Siemens BN ProSpec (nephelometry) [14]. The CKD-EPI equation for serum creatinine and cystatin c levels was used to estimate the estimated glomerular filtration rate, or eGFR (eGFRScr-Scys) [16].

Routine local measurements

Serum creatinine (Scr) levels were also measured locally (in the Biochemistry Department at the National Autonomous University of Nicaragua-Leon) using a ChemWell® 2910 (Awareness Technology, EEUU) auto analyser (Jaffe compensated method) [17, 18]. Local Scr values were multiplied by 0.95, as they were not calibrated to an IDMS-traceable creatinine standard [19]. Kidney function was calculated using the estimated glomerular filtration rate according to the CKD-EPI formula by determining Scr levels [16] at each study visit.

Urine markers

Creatinine and albumin levels in baseline urine samples, which were previously frozen and stored at − 80 °C for 2.5 years, were measured using the Jaffe and bromocresol green reactions (Sigma-Aldrich, MAK124), respectively. Samples were read at a specific wavelength using the Biochrom EZ Read 400 Microplate Reader. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) levels were measured in a subsample. Samples from fifty-five randomly selected participants with stable kidney function and samples from all participants in the other two subgroups (rapid decline in kidney function and patients with established renal dysfunction; both of which are defined below) were analysed. uNGAL levels were measured using enzyme-linked immunoassay (ELH-Lipocalin2, RayBiotech), according to the manufacturer’s instructions. Albumin and uNGAL levels are reported as ratios to urinary creatinine levels measured using the Jaffe method (Sigma-Aldrich, C4255) [14].

Definitions of outcome categories

A growth mixture model (GMM) was used to identify three sub-groups of kidney function in males using the gold standard eGFR after 2 years, as previously described [14]. A group with established renal dysfunction at baseline (mean eGFRScr-Scys: 58 mL/min/1.73 m2) was investigated, which for the purpose of this paper, is defined as case-group 1. Then, a group with normal baseline kidney function (mean eGFR: 112 mL/min/1.73 m2) showed a rapid decline in eGFRScr-Scys of − 18.2 mL/min/1.73 m2/year and were designated case-group 2, i.e., rapid decliners. The remaining study participants were ‘non-cases’ with stable kidney function, i.e., men with persistently stable kidney function (mean baseline eGFR: 116 mL/min/1.73 m2) and an annual decline in eGFRScr-Scys of only − 0.6 mL/min/1.73 m2/year over two years. The analyses compared each of the two case groups with the non-cases. Given the small number of affected females exhibiting a rapid decline in kidney function (3 cases), formal analyses were restricted to males.


Each participant completed a baseline questionnaire by face-to-face interview that included demographic data, current and previous occupations, lifestyle factors, medications, liquid intake, and dehydration symptoms [13, 14]. The season was defined as summer and winter. Work performed was classified as outdoor and indoor work. For this analysis, we used the eGFR and uNGAL levels, but in a sensitivity analysis the baseline questionnaire data (age, season, work performed, urinary albumin-creatinine ratio (UACR)) were included as part of the full model. UACR was categorized as a ratio ≥ 30 mg/g or < 30 mg/g [20].

Statistical analysis

Descriptive analyses of continuous variables (age, serum creatinine, eGFRScr, eGFRScr-Scys, and uNGAL) stratified by case/non-case status were conducted, and are reported as the means (SD) or medians and interquartile ranges (IQRs). Categorical variables (season, work performed and UACR) are reported as frequencies and percentages.

For the identification of cases of MeN in the local setting, local measurements are required; therefore, the current analysis is based on the routine creatinine measurements performed after each visit. The agreement between the estimated GFR based on the Scr Jaffe assay conducted at the laboratory in Nicaragua and the eGFRScr from Oxford (gold-standard measure) was evaluated at three time points (baseline, 6 and 12 months) using a Bland-Altman plot.

For case-group 1, we first assessed whether the routine eGFR data derived from local creatinine measurements identified people with established kidney damage. Logistic regression models were also performed to compare case-group 1 with non-cases. Model 1 included eGFRScr at baseline; Model 2 included the Model 1 covariate plus uNGAL levels. Along with variables included in Models 1 and 2, subsequent models for non-cases and case-group 2 also included the 6- and/or 12-month eGFR with or without uNGAL levels.

For all models, receiver operating characteristic (ROC) curves were generated to calculate the area under the ROC curve (AUC). An AUC greater than 0.80 was considered a suitable discrimination performance for the model.

In order to check that the results are not confounded, we repeated the analysis using only the continuous eGFR, and uNGAL measurements with further adjustments for other variables such us age, season, work performed, and urinary albumin-creatinine ratio (UACR) (Table 1).
Table 1

Variables outlined in each of the models stratified by case-groups


Case-group 1

Case-group 2

Model 1

Model 2

Model 3

Model 4

Model 5

Model 6

Model 7

Model 8

Model 9

Model 10























Occupation (outdoor work)

































eGFRScr at baseline











eGFRScr at 6 months







eGFRScr at 12 months






All statistical analyses were performed using Stata software, version 14 (Stata Corp.).


Agreement between clinical measurements – Routine eGFRScr-Nicaragua compared to the gold-standard eGFRScr-Oxford

In daily clinical practice, eGFRScr measurements are used, and we compared these values to gold-standard eGFRScr-Oxford. The mean difference in baseline kidney function based on serum creatinine levels measured in Nicaragua compared to serum creatinine levels measured in Oxford was − 10.47 mL/min/1.73 m2 (95% CI -11.90 to − 9.03), suggesting that Nicaraguan kidney function was overestimated by local measurements. The limits of agreement ranged from − 37.24 to 16.30 mL/min/1.73 m2 with a variability of 3.7%, suggesting that local measurements varied. No evidence of the measurement error in eGFRScr was observed, with a poor correlation between the difference and the sums (r = − 0.06; P = 0.213) (Additional file 1: Figure S1A). The mean difference in eGFRScr-Nicaragua after 6 months was − 8.39 mL/min/1.73 m2 (95% CI -9.91 to − 6.88), with a range of 22.07 to 152.35 mL/min/1.73 m2. The limits of agreement were − 35.09 to 18.30 mL/min/1.73 m2 and the variability was 5.4% (Additional file 1: Figure S1B). Finally, the mean difference in eGFRScr-Nicaragua at the third study visit was + 3.44 mL/min/1.73 m2 (95% CI 1.76 to 5.11), with a range of 15.54 to 146.33 mL/min/1.73 m2. The limits of agreement were − 26.90 to 33.17 mL/min/1.73 m2 and the variability was 7.2%. A weak correlation between the difference and the sums was observed for both lab results (r = − 0.11; P = 0.042) (Additional file 1: Figure S1C).

General characteristics stratified by kidney function trajectories

The mean age at baseline for the entire men population was 23.7 ± 3.8 years. The majority of males (74%) reported that they worked outdoors. Table 2 shows the routine local clinical kidney measurements at baseline stratified according to the observed renal outcome groups after 2 years of follow-up. At baseline, no differences were observed between controls and case-group 2. However, a subgroup of males had a high serum creatinine level and low eGFRScr at baseline, and were unaware of this condition at recruitment into the study (case-group 1). Case-group 1 displayed a high urinary uNGAL level at baseline. However, the percentages of males displaying a UACR ≥30 mg/g were 4.7% among participants with stable kidney function and 16% among participants with established renal dysfunction (case-group 1).
Table 2

Baseline characteristics of apparently healthy young men in northwest Nicaragua stratified by trajectories of a future decline in kidney function using gold standard measurements (CKDEPI Creat/Cyst eGFR) (n = 263)

Trajectories of the decline in kidney function


Age at baseline (Mean; SD)

Serum creatinine level at baseline‡ (Median; IQR)

eGFRScr at baseline‡ (Median; IQR)

eGFRScr-Scys at baseline† (Median; IQR)

Urinary NGAL level at baseline (Median; IQR)

UACR ≥30 mg/dL at baseline (n; %)

Outdoor work at baseline (n; %)

Stable kidney function (−0.6 mL/min/1.73 m2/year)


23.6 ± 3.89

0.76 (0.57–0.76)

131 (124–140)

118 (108–125)

5.04 (4.7–5.4)

10 (4.7)

151 (70.9)

Rapid decline in kidney function (− 18.2 mL/min/1.73 m2/year)


23.3 ± 3.65

0.66 (0.47–0.76)

132 (123–152)

117 (103–124)

5.20 (5.0–5.5)

0 (0)

24 (96.0)

Renal dysfunction (− 3.8 mL/min/1.73 m2/year)


25.4 ± 2.97

1.23 (1.14–1.52)

80 (62–91)

56 (49–68)

5.7 (5.5–5.7)

4 (16.0)

19 (76.0)



23.7 ± 3.82

0.76 (0.66–0.85)

129 (121–139)

116 (102–125)

5.20 (4.9–5.7)

14 (5.3)

194 (73.8)

‡Routine local test measurement. †Gold-standard outcome measured in Oxford 2 years later. Urinary biomarkers of kidney injury

Model for predicting established renal dysfunction

The prediction score comparing stable kidney function (non-cases) and established renal dysfunction (case-group 1) without uNGAL levels by using a single eGFRScr measurement was excellent (P < 0.001), showing an AUC of 0.97 (95% CI 0.93–1.00) (Additional file 1: Table S1; Model 1). The AUC for Model 2, where a single eGFRScr measurement and uNGAL levels did not improve the prediction compared with established predictors, was 0.98 (95% CI 0.95–1.00). The c statistic was the same for both models. (Fig. 1 and Additional file 1: Table S1).
Fig. 1
Fig. 1

ROC curves for the model predicting stable kidney function versus established renal dysfunction using eGFR and uNGAL. The 95% confidence intervals for the ROC curves (0.5) are displayed

Model for predicting a rapid decline in kidney function

The AUC just for the estimated glomerular filtration rate at baseline showed a poor discrimination to identify populations at risk of a rapid decline in kidney function (case-group 2). As shown in Fig. 2a, the discrimination power of the model at baseline was poor, with an AUC of 0.51 (95% CI 0.34–0.69), and when uNGAL was added to the logistic regression model, the AUC was 0.75 (95% CI 0.57–0.92). The c statistic for Model 4 with uNGAL levels was 0.24 higher, indicating a significant improvement compared with Model 3 that did not include uNGAL levels.
Fig. 2
Fig. 2

ROC curves for the model predicting stable kidney function versus a rapid decline in kidney function using eGFR and uNGAL. The 95% confidence intervals for ROC curves (0.5) are displayed. The blue label means: Area under the curve without uNGAL. The maroon label means: Area under the curve with uNGAL

Figure 2b shows the results of the model without uNGAL levels, but with an additional measurement of eGFRScr at 6 months (Model 5). The discrimination power of the model was somewhat improved (compared to Model 3), with an AUC of 0.71 (95% CI 0.56–0.85). For the same variables with the addition of uNGAL levels (Model 6), the AUC was 0.73 (95% CI 0.58–0.88). The c statistic for model 6 (with uNGAL levels) was 0.02.

Figure 2c shows the results of the models including an eGFRScr recorded 12 months after the baseline measure (excluding the 6-month measurement; Model 7), with an AUC of 0.80 (95% CI 0.70–0.91). The addition of uNGAL levels (Model 8) to this model yielded an AUC of 0.81 (95% CI 0.72–0.91). The c statistic was almost indistinguishable between model 7 and model 8, suggesting that uNGAL levels do not additional predictive value to model 7.

The best prediction of a future rapid decline in kidney function (Fig. 2d) was achieved using 3 eGFRScr measurements: baseline, 6 months and 12 months (Model 9). This model yielded an AUC of 0.88 (95% CI 0.79–0.98) and an AUC of 0.89 (95% CI 0.80–0.99) when urinary uNGAL levels were incorporated into the model (Model 10). Again, the c statistics were similar between Models 9 and 10 (Fig. 2 and Additional file 1: Table S2).

Results of the sensitivity analysis using eGFR, uNGAL measurements plus baseline questionnaire data (age, season, work performed, and UACR) were not appreciably changed when compared to the main analysis (Additional file 1: Figures S2 and S3 and Additional file 1: Table S3 and S4).


Using a gold-standard measurement of decline in kidney function, we classified the participants into three categories: (i) established renal dysfunction (case-group 1); (ii) a rapid decline in kidney function (case-group 2); and (iii) stable kidney function (non-cases). We then compared each of the two case-groups with the non-cases. While it was straightforward to identify individuals with already established renal dysfunction at baseline using routine laboratory data together with uNGAL (AUC: 0.98; 95% CI: 0.95 to 1.00), a follow-up for at least one year with 6 monthly measurements was required to identify most people who will suffer from a future rapid decline in kidney function from normal participants (AUC: 0.89; 95% CI: 0.80 to 0.99 and a false positive rate of 0.5). We did not observe a difference in the ROC values in the final model with and without uNGAL levels and note that the confidence intervals nearly overlapped.

Good quality laboratory results are very important for an accurate diagnosis and clinical decision making [2124]. The laboratory in Nicaragua is not accredited to ISO standards; however, as happens in routine clinical care, the machines are regularly recalibrated. Routine clinical care procedure do not standardly bank blood samples for several years to then retrospectively assess decline in kidney function. We showed that routine clinical care measurements displayed considerable time-dependent variability. The variability in the local Scr measurements increased the imprecision between the eGFRScr-Nicaragua and the gold-standard (eGFRScr-Oxford) of 3.7% at baseline and 7.2% at the third study visit. However, for the eGFR determinations performed following the baseline visit, measurement error appeared to have decreased as the laboratory obtaining a better machine recalibration, maintenance and the implementation of external quality control standards. Based on these findings, health care providers and researchers must be aware of the challenges of using local serum creatinine measurements.

To date, many prediction models have been developed and validated for determining the progression of kidney disease to ESRD [25, 26]. Roy et al. developed a prediction model and showed how a novel biomarker (uNGAL) improves prediction of CKD progression in the CRIC study [27]. Their model included demographic data plus uNGAL levels, and the model without uNGAL levels showed a poor discrimination power (AUC = 0.69), whereas the model with uNGAL levels exhibited good discrimination (AUC = 0.82). Our model with uNGAL levels used to distinguish participants with renal dysfunction (case-group 1) did not add predictive value beyond the established predictors (AUC = 0.98) compared to the model without uNGAL levels (AUC = 0.97).

When predicting a future rapid decline in kidney function (case-group 2), the addition of uNGAL levels to the model that included a single eGFRScr measurement increased the AUC from 0.51 to 0.75 (Model 3 vs Model 4). However, in the models including three eGFR measurements (Model 9 vs Model 10) the two curves were almost indistinguishable (e.g., AUCs with and without uNGAL levels were 0.88 and 0.89 respectively for models 9 and 10). Thus, no discernible improvement in prediction was observed when uNGAL levels were added to a model containing more than one creatinine measurement recorded over time.

The key implication from our study for future cohort and/or intervention studies of CKDu is that the minimal follow-up period is one year, and 6 monthly measurements are required to distinguish the progressive loss of eGFR from stable kidney function. Any study with a shorter follow-up period less likely to detect significant progression among participants with normal function at baseline.

Our study has methodological strengths. First, this study is derived from a community-based longitudinal study of apparently healthy young adults in high-risk areas for CKDu. Second, the variables that were used to calculate the prediction score are easy to obtain at any health level (i.e., primary, secondary and tertiary health levels) and can be applied by doctors or any health professional.

Our study has some limitations that should be noted. External validation was not performed because this community-based cohort study is the first in the region, and no other comparable cohorts are available. Second, we were unable to assess the effect of the season in which eGFR measures are performed because almost all participants were recruited before the harvest season [14].


In conclusion, established renal dysfunction was detected at a single time point using local measurements of eGFR and uNGAL. However, the detection of a rapid decline in kidney function over time requires at least 2 measurements, ideally at least twelve months apart. In addition, local routine clinical measurements of creatinine levels are affected by time-dependent measurement error.




Area under the receiver operating characteristic curve


Confidence interval


Centro de Investigación en Salud, Trabajo y Ambiente


Chronic kidney disease


Chronic Kidney Disease Epidemiology Collaboration


Chronic kidney disease of unknown aetiology


Chronic renal insufficiency cohort


Estimated glomerular filtration rate


End-stage renal disease


Growth mixture model


Isotope dilution mass spectrometry


Interquartile range


Mesoamerican nephropathy




Receiver operating characteristic


Serum creatinine


Serum cystatin C


Standard deviation


Urinary albumin-creatinine ratio


United Kingdom


Urinary neutrophil gelatinase-associated lipocalin



The authors would like to thank the participants and community leaders for their support during data collection over the two-year follow-up period. We would also like to thank the interview team, phlebotomists, drivers and staff of the Research Centre on Health, Work and Environment (CISTA) for their support during each data collection session. Many thanks to Team at the Clinical Trial Service Unit at Oxford University.


The study was funded by the UK Colt Foundation, and the Dutch National Postcode Lottery provided funding to Solidaridad. No funding source was involved in any part of the study design or the decision to submit the manuscript for publication.

Availability of data and materials

The dataset analysed in the current study is available from the corresponding author.

Authors’ contributions

This study was designed by MG, NP, BC and DN. Data were collected by MG, ES, NP and BC. Biological samples were analysed by ES. The data were analysed and interpreted by MG, ES, NP, BC and DN. All authors read and approved the final draft of the manuscript.

Ethics approval and consent to participate

The study was approved by the Institutional Review Boards at the Medical Faculty of UNAN-León (Ref: FWA00004523/IRB00003342) and the Research Ethics Committee of the London School of Hygiene and Tropical Medicine (Ref: 8643/14363) in 2014. A written consent form was provided by all participants in the follow-up study, in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Research Centre on Health, Work and Environment (CISTA), National Autonomous University of Nicaragua at León (UNAN-León), Campus Médico, Facultad de Ciencias Médica, edificio C, León, Nicaragua
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
Centre for Nephrology, University College London, London, UK


  1. Wegman D, Crowe J, Hogstedt C, Jakobsson K, Wesseling C, editors: Mesoamerican nephropathy: report from the second international research workshop on MeN. In: SALTRA. Edited by Central American Institute for Studies on Toxic Substances (IRET-UNA) and Program on Work EaHiCAS, vol. 33. Heredia, C.R: SALTRA/IRET-UNA; 2016.Google Scholar
  2. Wesseling C, Aragon A, Gonzalez M, Weiss I, Glaser J, Rivard C, Roncal-Jimenez C, Correa-Rotter R, Johnson RJ. Heat stress, hydration and uric acid: a cross-sectional study in workers of three occupations in a hotspot of mesoamerican nephropathy in Nicaragua. BMJ Open. 2016;6(12):1–12.View ArticleGoogle Scholar
  3. Ordunez P, Saenz C, Martinez R, Chapman E, Reveiz L, Becerra F. The epidemic of chronic kidney disease in Central America. Lancet Glob Health. 2014;2(8):e440–1.View ArticleGoogle Scholar
  4. Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;63(3):506–20.View ArticleGoogle Scholar
  5. Weiner DE, McClean MD, Kaufman JS, Brooks DR. The central American epidemic of CKD. Clin J Am Soc Nephrol. 2013;8(3):504–11.View ArticleGoogle Scholar
  6. Weaver VM, Fadrowski JJ, Jaar BG. Global dimensions of chronic kidney disease of unknown etiology (CKDu): a modern era environmental and/or occupational nephropathy? BMC Nephrol. 2015;16:145.View ArticleGoogle Scholar
  7. Garcia-Trabanino R, Trujillo Z, Colorado AV, Magana Mercado S, Henriquez CA. En nombre de la Asociacion de Nefrologia e Hipertension arterial de El S: prevalence of patients receiving renal replacement therapy in El Salvador in 2014. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2016;36(6):631–6.View ArticleGoogle Scholar
  8. Wesseling C, Crowe J, Hogstedt C, Jakobsson K, Lucas R, Wegman D, editors: First international research workshop on mesoamerican nephropathy (MeN). In: SALTRA. Edited by Central American Institute for Studies on Toxic Substances (IRET-UNA) and Program on Work EaHiCAS. Heredia, C.R.: SALTRA/IRET-UNA; 2013.Google Scholar
  9. Torres C, Aragon A, Gonzalez M, Lopez I, Jakobsson K, Elinder CG, Lundberg I, Wesseling C. Decreased kidney function of unknown cause in Nicaragua: a community-based survey. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2010;55(3):485–96.View ArticleGoogle Scholar
  10. Gonzalez-Quiroz M, Pearce N, Caplin B, Nitsch D. What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Mesoamerica?: a systematic review and meta-analysis. Clin Kidney J. 2017:1–11.Google Scholar
  11. Laws RL, Brooks DR, Amador JJ, Weiner DE, Kaufman JS, Ramirez-Rubio O, Riefkohl A, Scammell MK, Lopez-Pilarte D, Sanchez JM, et al. Biomarkers of kidney injury among Nicaraguan sugarcane workers. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2016;67(2):209–17.View ArticleGoogle Scholar
  12. Wesseling C, Aragon A, Gonzalez M, Weiss I, Glaser J, Bobadilla NA, Roncal-Jimenez C, Correa-Rotter R, Johnson RJ, Barregard L. Kidney function in sugarcane cutters in Nicaragua - a longitudinal study of workers at risk of Mesoamerican nephropathy. Environ Res. 2016;147:125–32.View ArticleGoogle Scholar
  13. Gonzalez-Quiroz M, Camacho A, Faber D, Aragon A, Wesseling C, Glaser J, Le Blond J, Smeeth L, Nitsch D, Pearce N, et al. Rationale, description and baseline findings of a community-based prospective cohort study of kidney function amongst the young rural population of Northwest Nicaragua. BMC Nephrol. 2017;18(1):16.View ArticleGoogle Scholar
  14. Gonzalez-Quiroz M, Smpokou ET, Silverwood RJ, Camacho A, Faber D, Garcia BR, Oomatia A, Hill M, Glaser J, Le Blond J, et al. Decline in kidney function among apparently healthy young adults at risk of Mesoamerican nephropathy. J Am Soc Nephrol. 2018;29:2200–12.View ArticleGoogle Scholar
  15. Laws RL, Brooks DR, Amador JJ, Weiner DE, Kaufman JS, Ramirez-Rubio O, Riefkohl A, Scammell MK, Lopez-Pilarte D, Sanchez JM, et al. Changes in kidney function among Nicaraguan sugarcane workers. Int J Occup Environ Health. 2015;21(3):241–50.View ArticleGoogle Scholar
  16. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.View ArticleGoogle Scholar
  17. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107–213.View ArticleGoogle Scholar
  18. Diagnostics R: Creatinine Jaffe G E N 2, Compensated Method for serum and Plasma. Mannheim: Roche Diagnostics. In. Edited by Diagnostics R: Roche Diagnostics; 2006.Google Scholar
  19. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Chronic kidney disease epidemiology C: expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766–72.View ArticleGoogle Scholar
  20. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.View ArticleGoogle Scholar
  21. Selvin E, Juraschek SP, Eckfeldt J, Levey AS, Inker LA, Coresh J. Within-person variability in kidney measures. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013;61(5):716–22.View ArticleGoogle Scholar
  22. Schmidt RL, Straseski JA, Raphael KL, Adams AH, Lehman CM. A risk assessment of the Jaffe vs enzymatic method for creatinine measurement in an outpatient population. PLoS One. 2015;10(11):e0143205.View ArticleGoogle Scholar
  23. Hoste L, Deiteren K, Pottel H, Callewaert N, Martens F. Routine serum creatinine measurements: how well do we perform? BMC Nephrol. 2015;16:21.View ArticleGoogle Scholar
  24. Padala S, Tighiouart H, Inker LA, Contreras G, Beck GJ, Lewis J, Steffes M, Rodby RA, Schmid CH, Levey AS. Accuracy of a GFR estimating equation over time in people with a wide range of kidney function. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2012;60(2):217–24.View ArticleGoogle Scholar
  25. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS. A predictive model for progression of chronic kidney disease to kidney failure. Jama. 2011;305(15):1553–9.View ArticleGoogle Scholar
  26. Bang H, Vupputuri S, Shoham DA, Klemmer PJ, Falk RJ, Mazumdar M, Gipson D, Colindres RE, Kshirsagar AV. SCreening for occult REnal disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med. 2007;167(4):374–81.View ArticleGoogle Scholar
  27. Roy J, Shou H, Xie D, Hsu JY, Yang W, Anderson AH, Landis JR, Jepson C, He J, Liu KD, et al. Statistical methods for cohort studies of CKD: prediction modeling. Clin J Am Soc Nephrol. 2017;12(6):1010–7.View ArticleGoogle Scholar


© The Author(s). 2019